Page 4,857«..1020..4,8564,8574,8584,859..4,8704,880..»

Physician First Choice Stem Cell Therapy (888) 828-4575 – Video

Posted: Published on October 9th, 2013

Physician First Choice Stem Cell Therapy (888) 828-4575 http://stemcelltreatmentclinic.com Physician First Choice offers US Board Certified stem cell doctors providing treatment in both the US and Mexico. Treatmen... By: USPainNetwork … Continue reading →

Comments Off on Physician First Choice Stem Cell Therapy (888) 828-4575 – Video

Stem Cell Therapy – Video

Posted: Published on October 9th, 2013

Stem Cell Therapy By: tscmru … Continue reading →

Comments Off on Stem Cell Therapy – Video

Q Therapeutics CEO to Present at Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa

Posted: Published on October 9th, 2013

SALT LAKE CITY, UT--(Marketwired - Oct 8, 2013) - Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that Deborah Eppstein, PhD, President and CEO, is scheduled to present at the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa. The 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures.The meeting features a nationally recognized Scientific Symposium, attended by leading scientists and researchers, in conjunction with the industry's premier annual Regen Med Partnering Forum.Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field. EVENT AT A GLANCE: Date: October 14, 2013 Time: 11:45 AM PT Location: Estancia La Jolla Hotel & Spa La Jolla Ballroom AB 9700 North Torrey Pines Road La Jolla, California To learn more or to register for the Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the … Continue reading →

Comments Off on Q Therapeutics CEO to Present at Third Annual Regen Med Partnering Forum at the 2013 Stem Cell Meeting on the Mesa

Simple urine test could help diagnose eye disease

Posted: Published on October 9th, 2013

Washington, Oct. 9 (ANI): A new study has claimed to have found the link between patient's urine to gene mutations that cause retinitis pigmentosa, or RP, an inherited, degenerative disease that results in severe vision impairment and often blindness. Ziqiang Guan, an associate research professor of biochemistry in the Duke University Medical School and a contributing author of the study, and his collaborators had previously sequenced the genome of this family and found that the children with RP carry two copies of a mutation at the dehydrodolichol diphosphate synthase (DHDDS) gene, which makes the enzyme that synthesizes organic compounds called dolichols. In humans, dolichol-19, containing 19 isoprene units, is the most abundant species. The DHDDS mutation, which was found in 2011, is the latest addition to more than 60 gene mutations that have been implicated in RP. This mutation appears to be prevalent in RP patients of the Ashkenazi Jewish origin, and 1 in 322 Ashkenazi carries one copy of the mutation. Guan said that he knew from his previous experience in analyzing urine samples from liver disease patients that I can readily detect dolichols by liquid chromatography and mass spectrometry. Using these techniques, he analyzed urine and blood samples … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Simple urine test could help diagnose eye disease

StemCells, Inc. Announces Closing of $18.6 Million Public Offering

Posted: Published on October 9th, 2013

NEWARK, Calif., Oct. 8, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that it has closed its previously announced underwritten public offering of common stock and warrants. The Company sold a total of 12,845,500 units, which includes the underwriter's full over-allotment option. The Company sold the units at a public offering price of $1.45 per unit and received total proceeds, net of offering expenses, underwriting discounts and commissions, of approximately $17.3 million. Each unit sold consists of one share of common stock, par value $.01 per share, and a warrant to purchase one half share of common stock. The warrants have an exercise price of $1.80 per share, are exercisable immediately, and will expire five years from the date of issuance. Chardan Capital Markets acted as sole bookrunner for the offering and Maxim Group LLC acted as co-manager. In connection with the offering, the Company terminated its $30 million equity purchase agreement with Lincoln Park Capital. Lincoln Park Capital participated in the offering as an investor. About StemCells, Inc. StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on StemCells, Inc. Announces Closing of $18.6 Million Public Offering

Healios K.K. Announces 3 Billion JPY (USD $30.6 Million) Capital Raise

Posted: Published on October 9th, 2013

TOKYO--(BUSINESS WIRE)-- Healios K.K. (Headquarters: Tokyo, Japan; President and CEO: Hardy TS Kagimoto M.D.), a Japanese bioventure company at the forefront of developing innovative therapies utilizing human induced pluripotent stem cell (hiPSC) technology, is pleased to announce that it has successfully raised its target capital of 3 billion JPY (USD $30.6 million). With completion of its capital campaign, which started in March 2013, Healios K.K. will continue development of promising new treatments for age-related macular degeneration (AMD) by hiPSC derived retinal pigment epithelium (RPE) cell transplantation under partnership with the following group of pioneering investors: Founded in February 24, 2011 Healios K.K. aims to commercialize the worlds first pharmaceutical hiPSC derived RPE cell transplantation for treatment of AMD in collaboration with RIKEN, one of the leading research institutes in Japan. The goal of this therapy is to promote the regeneration of retinal function and, consequently, to improve visual function in those affected with retinal degenerative diseases. The significance of the total raised capital fortifies the companys momentum in the development of therapeutics utilizing the Nobel Prize-winning hiPSC technology and attests its uncompromising commitment to making groundbreaking strides in the field of regenerative medicine. About Healios K.K. Company Name: Healios K.K. … Continue reading →

Comments Off on Healios K.K. Announces 3 Billion JPY (USD $30.6 Million) Capital Raise

Trio heading to B.C. to join finish of Craig Gives Back tour

Posted: Published on October 8th, 2013

NEW GLASGOW Bob MacDonald and Lloyd McLean are excited to get some company on the last leg of their Craig Gives Back tour. Lloyd McLean and Craig Aucoin. Vision Fire Studios Craig Aucoin, the original cyclist with the tour who was injured early on, along with MacDonalds wife Laureen and McLeans wife Andrea, will be joining the Lyons Brook men in late-October for the last three days of the journey. Craig is going to join us in Vancouver and I will get a bike somewhere and finish out the last leg with them, said MacDonald during a break from the tour in Calgary on Friday. Aucoin, with Laureen and Andrea, will fly out this month and plans are still being made for them each to have their bicycle when they arrive. MacDonald joined the Craig Gives Back tour in mid-August after Aucoin suffered an injury to his ankle and knee while cycling in Newfoundland with Lloyd McLean. Aucoin was expected to be back on the bike when it left Pictou County in mid-August, but he broke his wrist during another fall. MacDonald is partially sighted and like Aucoin; he also has retinitis pigmentosa. MacDonald said he is looking forward to … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on Trio heading to B.C. to join finish of Craig Gives Back tour

New bionic eye may help restore some vision in blind

Posted: Published on October 8th, 2013

A bionic eye may soon help give some sight back to people who lost their vision due to a degenerative eye disease. The Argus II by Second Sight, which was approved by the Food and Drug Administration in February, is set to hit the U.S. market soon. Specifically, the bionic eye can help people who suffer from retinitis pigmentosa, a rare disease that destroys the photoreceptor cells in the eye's retina. The retina is the tissue layer at the back of the inner eye responsible for converting images to nerve signals which are then sent to the brain. When the cells are damaged, the person cannot perceive light and dark. About 1 in every 4,000 people has the disease, according to government estimates. To restore light and dark vision, a chip containing many electrodes is implanted on the patient's retina. The patient wears a pair of glasses with a video camera attached to it. The camera wirelessly sends the recorded image to the electrodes in the chip, which then turns the information into a signal that the brain can understand. Dr. Jacque Duncan, a professor of ophthalmology at UCSF, explained to CNET's Sumi Das that the device allows the patient … Continue reading →

Posted in Retinitis Pigmentosa | Comments Off on New bionic eye may help restore some vision in blind

Vida Aesthetic Medicine: Is Ultherapy Painful? – Video

Posted: Published on October 8th, 2013

Vida Aesthetic Medicine: Is Ultherapy Painful? Real patients discuss their experiences getting Ultherapy. By: David Kenny … Continue reading →

Posted in Aesthetic Medicine | Comments Off on Vida Aesthetic Medicine: Is Ultherapy Painful? – Video

Stem Cells Delivered by Patch Effective in Repairing Cardiac Damage Weeks After Heart Attack Occurs

Posted: Published on October 8th, 2013

Durham, NC (PRWEB) October 08, 2013 A new study released today in Stem Cells Translational Medicine shows that in rats, treating a heart attack with stem cells even weeks after the attack occurred can halt deterioration and help the heart regenerate itself. In addition, the doctors delivered the cells using a patch that resulted in a higher survival rate for the stem cells and more of them migrating into the damaged tissue, where they went to work creating new blood vessels. The team, from the University of Louisvilles Cardiovascular Innovation Institute (Louisville, KY), had previously shown in rat studies that stem cell treatment immediately following an attack aided recovery by improving blood flow in the smallest vessels of the heart. This time the goal was to determine if the treatment was still effective if applied later in time. We also were seeking a more efficient delivery method for the stem cells by utilizing the heart patch model. Most studies employing an injection of stem cells encounter swift cell death or cell washout from the target tissue, said Amanda LeBlanc, Ph.D., who led the investigation along with Stuart Williams, Ph.D., the institutes executive and scientific director. They tested their theory by … Continue reading →

Comments Off on Stem Cells Delivered by Patch Effective in Repairing Cardiac Damage Weeks After Heart Attack Occurs

Page 4,857«..1020..4,8564,8574,8584,859..4,8704,880..»